| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Epidemiology and Prevention |
1 Centre for Clinical and Population Sciences, Queen's University; 2 Royal Group of Hospitals, Belfast, Northern Ireland; 3 Ulster Hospital, Dundonald, Northern Ireland; 4 National Cancer Registry, Cork, Ireland; and 5 St. James's Hospital, Dublin, Ireland
Requests for reprints: Lesley A. Anderson, Centre for Clinical and Population Sciences, Queen's University, Mulhouse Building, Grosvenor Road, Belfast, Northern Ireland BT12 6BJ. Phone: 44-28-9063-5046; Fax: 44-28-9024-8017; E-mail: l.anderson{at}qub.ac.uk.
Observational studies suggest that nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the risk of esophageal adenocarcinoma, but it is not known at what stage they may act in the esophageal inflammation-metaplasia-adenocarcinoma sequence. In an all-Ireland case-control study, we investigated the relationship between the use of NSAIDs and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma. Patients with esophageal adenocarcinoma, long-segment Barrett's esophagus and population controls were recruited from throughout Ireland. Esophagitis patients were recruited from Northern Ireland only. Data were collected on known and potential risk factors for esophageal adenocarcinoma and on the use of NSAIDs, including aspirin, at least 1 year before interview. Associations between use of NSAIDs and the stages of the esophageal inflammation-metaplasia-adenocarcinoma sequence were estimated by multiple logistic regression. In total, 230 reflux esophagitis, 224 Barrett's esophagus, and 227 esophageal adenocarcinoma and 260 population controls were recruited. Use of aspirin and NSAIDs was associated with a reduced risk of Barrett's esophagus [odds ratio [OR; 95% confidence interval (95% CI)], 0.53 (0.31-0.90) and 0.40 (0.19-0.81), respectively] and esophageal adenocarcinoma [OR (95% CI), 0.57 (0.36-0.93) and 0.58 (0.31-1.08), respectively]. Barrett's esophagus and esophageal adenocarcinoma patients were less likely than controls to have used NSAIDs. Selection or recall bias may explain these results and the results of previous observational studies indicating a protective effect of NSAIDs against esophageal adenocarcinoma. If NSAIDs have a true protective effect on the esophageal inflammation-metaplasia-adenocarcinoma sequence, they may act early in the sequence. (Cancer Res 2006; 66(9): 4975-82)
This article has been cited by other articles:
|
|
 |
|
  L A Anderson, S J Murphy, B T Johnston, R G P Watson, H R Ferguson, K B Bamford, A Ghazy, P McCarron, J McGuigan, J V Reynolds, et al. Relationship between Helicobacter pylori infection and gastric atrophy and the stages of the oesophageal inflammation, metaplasia, adenocarcinoma sequence: results from the FINBAR case-control study Gut, June 1, 2008; 57(6): 734 - 739. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sadeghi, C. J. Bain, N. Pandeya, P. M. Webb, A. C. Green, D. C. Whiteman, and for the Australian Cancer Study Aspirin, Nonsteroidal Anti-inflammatory Drugs, and the Risks of Cancers of the Esophagus Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1169 - 1178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. R. Ferguson, C. P. Wild, L. A. Anderson, S. J. Murphy, B. T. Johnston, L. J. Murray, R.G. P. Watson, J. McGuigan, J. V. Reynolds, and L. J. Hardie Cyclooxygenase-2 and Inducible Nitric Oxide Synthase Gene Polymorphisms and Risk of Reflux Esophagitis, Barrett's Esophagus, and Esophageal Adenocarcinoma Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 727 - 731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. R. Ferguson, C. P. Wild, L. A. Anderson, S. J. Murphy, B. T. Johnston, L. J. Murray, R.G. P. Watson, J. McGuigan, J. V. Reynolds, and L. J. Hardie No Association between hOGG1, XRCC1, and XPD Polymorphisms and Risk of Reflux Esophagitis, Barrett's Esophagus, or Esophageal Adenocarcinoma: Results from the Factors Influencing the Barrett's Adenocarcinoma Relationship Case-Control Study Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 736 - 739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Duan, A. H. Wu, J. Sullivan-Halley, and L. Bernstein Nonsteroidal Anti-inflammatory Drugs and Risk of Esophageal and Gastric Adenocarcinomas in Los Angeles County Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 126 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Murphy, A. E. Hughes, C. C. Patterson, L. A. Anderson, R.G.P. Watson, B. T. Johnston, H. Comber, J. McGuigan, J. V. Reynolds, and L. J. Murray A population-based association study of SNPs of GSTP1, MnSOD, GPX2 and Barrett's esophagus and esophageal adenocarcinoma Carcinogenesis, June 1, 2007; 28(6): 1323 - 1328. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
